Core Insights - The company is focusing on expanding its online sales through major e-commerce platforms like JD.com, Taobao, and Pinduoduo, while also enhancing its O2O (Online to Offline) business model to seek new growth points [1] - A new pharmaceutical marketing management center has been established to strengthen professional service capabilities, with measures in place to revitalize slow-moving and unsold products [1] - The company aims to create a closed-loop ecosystem in the pharmaceutical industry by enhancing product supply from its manufacturing segment and improving customer retention through membership and pharmaceutical services [1] Sales and Marketing Strategy - The company is consolidating its market position for key products like injection-grade ribonucleic acid II through a clinical-to-terminal sales model and optimizing performance assessments for clinical personnel [1] - Plans include hosting marketing summits and academic seminars to cover hospital terminals and promote resource coverage nationwide [1] - The company is accelerating market penetration for selected products through centralized procurement and aims to achieve sales growth with newly approved products [2] Research and Development - The company is actively exploring traditional Chinese medicine and conducting research in various therapeutic areas, including cancer, kidney disease, diabetes, and cardiovascular diseases [3] - Multiple generic drug approvals have been obtained, including phosphoric acid oseltamivir capsules and others, indicating a steady progression in R&D projects [3] Technological Integration - The company is leveraging AI technology to optimize drug screening and clinical trial design, moving towards a smart manufacturing model that emphasizes high quality and efficiency [4] - A marketing reform initiative has been launched to establish a unified command and collaborative marketing system, enhancing strategic coordination and operational awareness across the organization [4]

4、请介绍一下公司化学药品产品及发展情况。 2024 年，公司化学药品板块实现营业收入 27,685.38 万元， 占营业收入比重为 10.61%，化学药品包括化学药品针剂、化学 药品普药和化药原料药。公司化药治疗领域包括：抗肿瘤药物、 免疫调节药物、抗感染药物、心血管系统疾病、消化系统及代 谢疾病、内分泌及代谢疾病等。公司以终端市场深度开发驱动 增长，核心品种注射用核糖核酸 II 通过完善营销体系实现结构 性突破：自建终端团队覆盖万余家专业诊所，2024 年销量达 182.7 万支，同比增加 20 万支，为产品下一步销售奠定基础。 优势品种注射用盐酸平阳霉素构建循证医学壁垒，联合上海九 院开展静脉畸形联合用药临床研究，治疗恶性胸腔积液疗效获 多省验证，权威期刊发布三大病种诊疗共识，临床数据驱动销 售持续拓展。终端控销队伍，加速产品布局，以营养神经为主 的乙酰谷酰胺注射液、治疗肝病的肝水解肽注射液、营养心肌 为主的注射用左卡尼汀等潜力品种销售稳步推进。注射用丁二 磺酸腺苷蛋氨酸、注射用盐酸地尔硫卓、注射用尿激酶、注射 用盐酸丙帕他莫等多款产品中标多省联盟集采，集采品种实现 "以量换价"，销售稳健。新获批品种快 ...